A share price of Akero Therapeutics Inc [AKRO] is currently trading at $54.08, down -2.31%. An important factor to consider is whether the stock is rising or falling in short-term value. The AKRO shares have gain 106.57% over the last week, with a monthly amount glided 93.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
Akero Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $15.32 and $58.40. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $54.08 at the most recent close of the market. An investor can expect a potential drop of -7.54% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -948.14%, Pretax Profit Margin comes in at -835.29%, and Net Profit Margin reading is -835.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 52.69 points at the first support level, and at 51.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 55.68, and for the 2nd resistance point, it is at 57.27.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akero Therapeutics Inc [NASDAQ:AKRO] is 17.25. On the other hand, the Quick Ratio is 17.25, and the Cash Ratio is 7.3.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on Jan 27 ’25 when 53590.0 shares were sold. Chief Development Officer, Yale Catriona completed a deal on Jan 27 ’25 to sell 49074.0 shares. Meanwhile, Chief Scientific Officer Rolph Timothy sold 31250.0 shares on Jan 27 ’25.
